<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621709</url>
  </required_header>
  <id_info>
    <org_study_id>ACUN-VALV-001</org_study_id>
    <nct_id>NCT03621709</nct_id>
  </id_info>
  <brief_title>CoreValve™ Evolut R™ 34 mm System Registry (CoreValve34)</brief_title>
  <acronym>TAVI34mm</acronym>
  <official_title>Multicenter Ambispective Study of Clinical Outcomes of the CoreValve™Evolut R™ 34mm System: All Comers Post-market Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacin Biomedica Galicia Sur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacin Biomedica Galicia Sur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the introduction of the CoreValve™ Evolut R™ 34mm (Medtronic™) prosthesis, patients with
      severe symptomatic aortic stenosis (AS) and large aortic annulus have become eligible for
      transcatheter aortic valve implantation (TAVI). The aim of this study is to detect the number
      of TAVI candidates with large aortic annulus, and to evaluate the feasibility, efficacy, and
      safety of TAVI using the CoreValve™ Evolut R™ 34mm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the current transcatheter valves available in the market, is possible to cover a wide
      range of patients with diverse and complex anatomies. Nevertheless, there is a subgroup of
      patient with large aortic annulus (diameter &gt; 27 mm), in whom the implant of a transcatheter
      valve is not possible because there is no valve suitable for such as aortic annulus size.

      With the introduction of the CoreValveTM EvolutionTM R 34mm, patients with an aorttic annulus
      dimension up to 29 mm in diameter have become eligible for TAVI. However, there is a lack of
      information regarding the number of patient with AS and this particular anatomy of the aortic
      annulus. Italian and Dutch registries have reported a prevalence between 6.5 to 12.3% with
      large aortic annulus requiring the previous CoreValveTM 31mm. Yet, there is no reported data
      regarding this population of patients in Spain. Also, the clinical use of this larger
      prosthesis covers a wider range of aortic rings and may enchance the procedural challenges,
      such as a little margin for proper valve placement, more likelihood of interference with
      mitral valve function and damage to the cardiac conduction system during the prosthesis
      deployment.

      So far, no studies regarding clinical experiences with the CoreValveTM EvolutionTM R 34mm
      have been published. The scarce information currently available with this new device may be
      distant from those found in its daily clinical use in non-selected patients. The results of
      this Spanish nationwide registry will help to answer a scientific need of information
      regarding acute procedural results and mid
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke (disabling), dichotomous qualitative variable: yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: prosthetic regurgitation at early post TAVI</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of subjects with ≤ mild prosthetic regurgitation at early post-implant (mild, Moderate or Severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety:Incidence of permanent pacemaker implant rate</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of permanent pacemaker implant rate, dichotomous qualitative variable: yes/no</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <arm_group>
    <arm_group_label>CoreValve™ Evolut R™ 34mm</arm_group_label>
    <description>All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with severe symptomatic aortic stenosis undergo TAVI using the CoreValve™
        Evolut R™ 34 mm will be included
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 18 years of age.

          -  Subject accepted participate and signed informed consent.

          -  Subject with severe symptomatic AS patients selected for TAVI by the Heart Team of
             each participating hospital.

          -  Patients anatomically suitable for the implantation of a CoreValve™ Evolut R™ 34mm
             with the approved indications by any feasible and appropriate vascular routes.

          -  Subject must agree to undergo all follow-up visits

        Exclusion Criteria:

          -  High probability of non-adherence to the follow-up requirements.

          -  Explicit refusal of participation in the registry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor A Jiménez Díaz, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Álvaro Cunqueiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Jiménez Díaz, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Álvaro Cunqueiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005 Jun 21;111(24):3316-26. Review.</citation>
    <PMID>15967862</PMID>
  </reference>
  <reference>
    <citation>Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013 Sep 10;62(11):1002-12. doi: 10.1016/j.jacc.2013.05.015. Epub 2013 May 30.</citation>
    <PMID>23727214</PMID>
  </reference>
  <reference>
    <citation>Otto CM. Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol. 2006 Jun 6;47(11):2141-51. Epub 2006 May 15. Review.</citation>
    <PMID>16750677</PMID>
  </reference>
  <reference>
    <citation>Carabello BA. Aortic stenosis: a fatal disease with but a single cure. JACC Cardiovasc Interv. 2008 Apr;1(2):127-8. doi: 10.1016/j.jcin.2007.12.004.</citation>
    <PMID>19463289</PMID>
  </reference>
  <reference>
    <citation>Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26.</citation>
    <PMID>17259184</PMID>
  </reference>
  <reference>
    <citation>Gherli T, Colli A, Fragnito C, Nicolini F, Borrello B, Saccani S, D'Amico R, Beghi C. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004 Aug 3;110(5):496-500.</citation>
    <PMID>15289387</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. doi: 10.1056/NEJMoa1103510. Epub 2011 Jun 5.</citation>
    <PMID>21639811</PMID>
  </reference>
  <reference>
    <citation>Attizzani GF, Ohno Y, Latib A, Petronio AS, Giannini C, Ettori F, Curello S, Bedogni F, Todaro D, Brambilla N, Bruschi G, Colombo P, Presbitero P, Fiorilli R, Poli A, Martina P, Colombo A, Barbanti M, Tamburino C. Acute and long-term (2-years) clinical outcomes of the CoreValve 31mm in large aortic annuli: A multicenter study. Int J Cardiol. 2017 Jan 15;227:543-549. doi: 10.1016/j.ijcard.2016.10.104. Epub 2016 Nov 1.</citation>
    <PMID>27816304</PMID>
  </reference>
  <reference>
    <citation>Nijhoff F, Agostoni P, Amrane H, Latib A, Testa L, Oreglia JA, De Marco F, Samim M, Bedogni F, Maisano F, Bruschi G, Colombo A, Van Boven AJ, Stella PR. Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and large aortic annulus, using the self-expanding 31-mm Medtronic CoreValve prosthesis: first clinical experience. J Thorac Cardiovasc Surg. 2014 Aug;148(2):492-9.e1. doi: 10.1016/j.jtcvs.2013.09.059. Epub 2013 Nov 19.</citation>
    <PMID>24263005</PMID>
  </reference>
  <reference>
    <citation>Cilingiroglu M, Hakeem A. Fate of mitral regurgitation following transcatheter aortic valve implantation: the achilles heel of core valve? Catheter Cardiovasc Interv. 2011 Oct 1;78(4):645-6. doi: 10.1002/ccd.23359.</citation>
    <PMID>21953759</PMID>
  </reference>
  <reference>
    <citation>Bleiziffer S, Ruge H, Hörer J, Hutter A, Geisbüsch S, Brockmann G, Mazzitelli D, Bauernschmitt R, Lange R. Predictors for new-onset complete heart block after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010 May;3(5):524-30. doi: 10.1016/j.jcin.2010.01.017.</citation>
    <PMID>20488409</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

